Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1480572
This article is part of the Research Topic Unveiling Biomarkers and Mechanisms in the Tumor-Immune Nexus View all 25 articles

Deciphering the Role of NcRNAs in Pancreatic Cancer Immune Evasion and Drug Resistance: A New Perspective for Targeted Therapy

Provisionally accepted
Yu Gong Yu Gong 1Desheng Gong Desheng Gong 2Sinian Liu Sinian Liu 3Xiangjin Gong Xiangjin Gong 1Jingwen Xiong Jingwen Xiong 1Jinghan Zhang Jinghan Zhang 1Lai Jiang Lai Jiang 1Jie Liu Jie Liu 2Lin Zhu Lin Zhu 2Huiyang Luo Huiyang Luo 4Ke Xu Ke Xu 4Xiaoli Yang Xiaoli Yang 2*Bo Li Bo Li 1*
  • 1 Southwest Medical University, Luzhou, China
  • 2 The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • 3 Xichong County People's Hospital, Nanchong, Anhui Province, China
  • 4 Chongqing General Hospital, Chongqing, Chongqing, China

The final, formatted version of the article will be published soon.

    Pancreatic cancer (PC) is a very aggressive digestive system tumor, known for its high mortality rate, low cure rate, low survival rate and poor prognosis. In particular, pancreatic ductal adenocarcinoma (PADC), which accounts for more than 90% of PC cases, has an overall 5-year survival rate of only 5%, which is an extremely critical situation. Early detection and effective treatment of PC is extremely difficult, which leads many patients to despair. In the current medical context, targeted therapy, as an important strategy for cancer treatment, is expected. However, the problems of immune escape and drug resistance in PC have become two major obstacles that are difficult to be overcome by targeted therapy. How to break through these two difficulties has become a key issue to be solved in the field of PC therapy. In recent years, non-coding RNAs (ncRNAs) have continued to heat up in the field of cancer research. NcRNAs play a pivotal role in gene regulation, cell differentiation, development, and disease processes, and their important roles in the genesis, development, and therapeutic response of PC have been gradually revealed. More importantly, ncRNAs have many advantages as therapeutic targets, such as high specificity and low side effects, making them a new favorite in the field of PC therapy. Therefore, the aim of this paper is to provide new ideas and methods for the targeted therapy of PC by reviewing the mechanism of action of four major ncRNAs (circRNAs, lncRNAs, miRNAs, siRNAs) in both immune escape and drug resistance of PC. It is expected that an effective way to overcome immune escape and drug resistance can be found through in-depth study of ncRNA, bringing a ray of hope to PC patients.

    Keywords: Tumor-immune interactions, ncRNA, Tumor immune microenvironment, targeted therapy, Pancreatic Cancer

    Received: 14 Aug 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Gong, Gong, Liu, Gong, Xiong, Zhang, Jiang, Liu, Zhu, Luo, Xu, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoli Yang, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China
    Bo Li, Southwest Medical University, Luzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.